The U.S. Food and Drug Administration has approved another over-the-counter naloxone nasal spray, widening the number of nonprescription options available for people who may need to reverse a suspected opioid overdose before emergency responders arrive.
The newly approved product, Rextovy, is a 4 milligram naloxone hydrochloride nasal spray for the emergency treatment of opioid overdose. In a June 16, 2026 announcement, the FDA said consumers will be able to buy it without a prescription in pharmacies, convenience stores and online.
The approval is not a cure for the overdose crisis, and it should not be treated as one. But it is a meaningful access decision: in an overdose, minutes matter, and the person most likely to act first may be a friend, relative, co-worker, bystander or store employee rather than a clinician.
What the FDA approved
Naloxone rapidly reverses the effects of opioids and is considered the standard emergency treatment for opioid overdose. Rextovy contains the same active ingredient as other naloxone nasal sprays, according to the FDA, and the agency granted the nonprescription approval to Amphastar Pharmaceuticals.
In the FDA’s release, Mike Davis, acting director of the Center for Drug Evaluation and Research, said adding another OTC naloxone nasal spray broadens access and gives consumers another option. The agency also said availability of multiple approved formulations can improve market supply, create competition and offer alternative sourcing options.
That market detail matters more than it sounds. A product can be legally available and still be practically hard to find if a local pharmacy is out of stock, a price is too high, a purchaser feels stigma at the counter, or a community program cannot source enough doses. Another OTC option does not eliminate those barriers, but it gives public health teams, retailers and families one more route.
“Immediate access to naloxone nasal sprays is essential when a person is experiencing an overdose.”
Karen Murry, M.D., FDA Office of Nonprescription Drug Products
What changes for consumers
The practical change is straightforward: Rextovy can be sold directly to consumers without an individual prescription. That expands the over-the-counter shelf of opioid overdose reversal products, which matters most for people who want to keep naloxone at home, in a workplace, in a car, at an event, or in a community setting where overdoses are possible.
The FDA’s broader consumer guidance is blunt about why access matters. In an updated consumer page, the agency says naloxone can reverse the powerful effects of opioids when sprayed into the nose or injected. It also emphasizes that naloxone is temporary treatment; people should still call 911 and stay with the person until emergency medical help arrives.
| Question | What the FDA action means | What it does not mean |
|---|---|---|
| Can people buy Rextovy without a prescription? | Yes. FDA says consumers may purchase it directly in places such as pharmacies, convenience stores and online. | Availability can still vary by retailer, price, stock and local distribution. |
| Does naloxone replace emergency care? | No. FDA says product instructions include calling 911 after giving the first dose. | It is not a substitute for monitoring, rescue breathing, medical evaluation or follow-up care. |
| Is it only for trained professionals? | No. FDA says OTC naloxone products are intended to be usable by people without medical training. | People should still learn overdose signs and read the product directions before an emergency. |
| Does this solve the overdose crisis? | No. It is one access tool in a larger public health response. | Prevention, treatment, harm reduction, mental health care and recovery support remain necessary. |
The safety message to keep clear
The FDA says Rextovy packaging includes pictorial directions with five steps, including calling 911 after the first dose. The agency also notes that some people may have symptoms when they regain consciousness after overdose reversal, including shaking, sweating, nausea or anger.
For readers, the most important health message is not brand-specific. Naloxone is meant for suspected opioid overdose, which can involve prescription opioids or illicit drugs such as heroin or fentanyl. FDA consumer materials list warning signs such as unresponsiveness, shallow breathing, limpness, blue lips, gums or fingertips, and slow or irregular heartbeat or pulse.
In a real emergency, hesitation can be deadly. The FDA says naloxone will generally not harm someone who does not have opioids in their system, and the newly approved product’s instructions direct users to seek emergency help after administering it.
Why another OTC spray matters now
The FDA framed the decision against the continuing toll of synthetic opioids, especially illicit fentanyl. The agency cited provisional overdose death data showing deaths fell from 111,451 in the 12-month period ending in August 2023 to 68,632 in the 12-month period ending in December 2025, while warning that overdose remains a major U.S. public health problem.
That is the tension behind the approval. The trend line may have improved, but the floor is still far too high. More OTC naloxone options can make reversal medicine easier to carry, stock and distribute, but the best version of this story is not a nasal spray on a shelf. It is a chain of readiness: someone recognizes the signs, gives the medication, calls 911, stays nearby, and the person survives long enough to reach care.
Rextovy adds one more link to that chain. The public health test is whether it reaches the homes, workplaces, outreach teams and ordinary bystanders who may have only a few minutes to use it.
